A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients with other clinical manifestations of atherosclerotic cardiovascular ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

A shocking new study reveals that a condition that can lead to limb amputation is far more prevalent and deadly than ...

A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million Americans over the age of 40, is often underdiagnosed and undertreated ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

Discover why remnant cholesterol, not LDL, is key to peripheral artery disease. Learn implications for prevention.